Also of note is the clinical stage buyout. Pre-clinical and...

First 68 Last

Share
Profile

Follow
Hodgie28

601 Posts.

839

24/11/21

15:12

Post #: 57819863
Share

Originally posted by Hodgie28: ↑

Apolgies @theoc have tried to rack the old grey matter for PRC but failed - found these though:

'Peoples Republic of China' and 'Pre-run crap'!

On the market cap front. IMO its important that IMM is recognised for its achievements in the clinic by gradual appreciation of MC.

Why is this important other than rewarding long term SH's with options to sell for a capital gain? Noting most long termers was in pre-SP consolidation - equivalent to to 4.9c today.

Looking at the top 10 biotech buy-outs last year (from $39 - $2 billion), the average premium paid from previous day SP is only 70%.
An example of how a target ASX listed biotech SP was continuously sold down over 6 months by 50% and then BP offered 100% premium at the bottom was Viralytics. Sold for $500 million.

The argument against this is that major SH's (Ridgeback in our case for example) would never 'under sell' the real value of IMM. But I would suggest all the companies involved in above would all have major cornerstone SH's and 70% premium was good enough for them - on the assumption historical SP trajectory has been upwards.

I believe the AFR alluded to a potential opportunistic bid for Immutep due its recent fall in SP and they may not be far off the mark???

Expand

Also of note is the clinical stage buyout. Pre-clinical and P2......

IMM Price at posting: 49.5¢ Sentiment: Buy Disclosure: Held
7 Upvote

0 Great analysis

Reply

Top Stories

HVN

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

PAR

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

CXU

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

88E

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

There are more pages in this discussion • 21 more messages in this thread...

First 68 Last

Add IMM (ASX) to my watchlist

(20min delay)
Last 35.8¢		Change 0.018(5.15%)		Mkt cap ! $501.1M

Open	High	Low	Value	Volume
34.0¢	36.0¢	33.5¢	$1.021M	2.928M

Buyers (Bids)

No.	Vol.	Price($)
5	33395	35.5¢

Sellers (Offers)

Price($)	Vol.	No.
36.0¢	196402	19

View Market Depth

No.	Vol.	Price($)
14	968414	0.350
7	135057	0.345
13	276818	0.340
11	249680	0.335
12	204346	0.330

Price($)	Vol.	No.
0.355	98613	4
0.360	175267	12
0.365	154504	14
0.370	187052	9
0.375	99142	4

Last trade - 12.21pm 18/09/2024 (20 minute delay)

IMM (ASX) Chart

Also of note is the clinical stage buyout. Pre-clinical and...

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Also of note is the clinical stage buyout. Pre-clinical and...

Top Stories

Harvey Norman clocks subdued gains as Echo Law's junk warranty class action kicks off

FDA hands Paradigm Biopharma guidance to re-jig phase 3 osteo trial – or is it a delay?

ASX Market Open: Australian bourse to fall as subdued Wall Street awaits rate cut decision | September 18, 2024

Cauldron discovers shallow uranium up to 2km at WA's Yanrey

HotCopper users smell capital raising as 88 Energy says "significant update" at Phoenix

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News